References
- Bachur N. R. Cytoplasmic aldo-keto reductases: A class of drug metabolizing enzymes. Science 1976; 193: 595–597
- Baltzer V., Schmutz M. Experimental anti-convulsive properties of GP 47 680 and GP 47 779, its main human metabolite; compounds related to carbamazepine. Advances in Epileptology-1977, H. Meinardi, A. J. Rowan. Suets & Zeitlinger B.V., Amsterdam and Lisse 1978; 295–299
- Eichelbaum M., Tomson T., Tybring G., Bertilsson L. Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. Clinical Pharmacokinetics 1985; 10: 80–90
- Faigle J. W., Brechbühler S., Feldmann K. F., Richter W. J. The biotransformation of carbamazepine. Epileptic seizures-behaviour-pain, W. Birkmayer. Hans Huber Publishers, Berne 1976; 127–140
- Faigle J. W., Feldmann K. F. Carbamazepine, biotransformation. Antiepileptic Drugs, D. M. Woodbury, J. K. Penry, C. E. Pippenger. Raven Press, New York 1982; 483–495
- Farghali-Hassan, Assael B. M., Bossi L., Garattini S., Gerna M., Gomeni R., Morselli P. L. Carbamazepine pharmacokinetics in young, adult and pregnant rats. Relation to pharmacological effects. Archives Internationales de Pharmacodynamie et de Therapie 1976; 230: 125–139
- Feldmann K. F., Brechbühler S., Faigle J. W., Imhof P. Pharmacokinetics and metabolism of GP 47 680, a compound related to carbamazepine, in animals and man. Advances in Epileptology-1977, H. Meinardi, A. J. Rowan. Swets & Zeitlinger B.V., Amsterdam and Lisse 1978; 290–294
- Feldmann K. F., Dörhöfer G., Faigle J. W., Imhof P. Pharmacokinetics and metabolism of GP 47 779, the main human metabolite of oxcarbazepine (GP 47 680) in animals and healthy volunteers. Advances in Epileptology, The XIIth Epilepsy International Symposium, M. Dam, L. Gram, J. K. Penry. Raven Press, New York 1981; 89–96
- International Index of Laboratory Animals, M. F. W. Festing, W. Butler. Medical Research Council, Laboratory Animals Centre, Carshalton, Surrey 1975
- Mazel P. Experiments illustrating drug metabolism in vitro. Fundamentals of Drug Metabolism and Drug Disposition, B. N. LaDu, H. G. Mandel, E. L. Way. The Williams & Wilkins Company, Baltimore 1971; 546–582
- Miller G. L. Protein determination for large numbers of samples. Analytical Chemistry 1959; 31: 964
- Omura T., Sato R. The carbon monoxide-binding pigment of liver microsomes. I: Evidence for its hemoprotein nature. The Journal of Biological Chemistry 1964; 239: 2370–2378
- Otani G., Abou-El-Makarem M. M., Bock K. W. UDP-Glucuronyltransferase in perfused rat liver and in microsomes. III. Effects of galactosamine and carbon tetrachloride on the glucuronidation of 1-naphthol and bilirubin. Biochemical Pharmacology 1976; 25: 1293–1297
- Rai P. V. Clinical trial for the estimation of anticonvulsive properties and side reactions of a new drug ketocarbamazepine. Advances in Epileptology. The Xth Epilepsy International Symposium, J. A. Wada, J. K. Penry. Raven Press, New York 1980; 357
- Reinikainen K., Keränen T., Hallikainen E., Riekkinen P. J. Substitution of diphenylhydantoin by oxcarbazepine or carbamazepine: double-blind study. Acta Neurologica Scandinavica 1984; 69(Suppl.)89–90
- Schütz H., Feldmann K. F., Faigle J. W., Kriemler H. P., Winkler T. The metabolism of [14C]oxcarbazepine in man. Xenobiotica 1986; 16: 769–778
- Theisohn M., Heimann G. Disposition of the antiepileptic oxcarbazepine and its metabolites in healthy volunteers. European Journal of Clinical Pharmacology 1982; 22: 545–551
- Wagner J., Schmid K. (1980) Induction of hepatic microsomal enzymes in rat liver by carbamazepine and related compounds. Seventh European Workshop on Drug Metabolism, Zurich, October, 5–101980, 239, Abstract Volume